FindTrial
Sign In

Effectiveness of intramuscular ketamine with other treatment of resistance unipolar depression patients

Efficacy of intramuscular ketamine as an adjunctive treatment in resistant unipolar depression-a double blind randomized placebo controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/053136
Enrollment
60
Registered
2023-05-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F32- Major depressive disorder, singleepisode

Interventions

Intervention1: Intramuscular Ketamine injection: Patients fit for ketamine injection will be kept NPM for at least 6 hours for clear fluid and 8hours for solid. 7. Bodyweight of each patient will be

Sponsors

Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Resistant uni-polar depression patients - patients who have diagnosed major depressive disorder according to ICD 10 by two different psychiatrist & patient who already received maximum dose of two antidepressant for 6-8 weeks

Exclusion criteria

Exclusion criteria: 1. Current substance abuse 2.mental retardation, pervasive developmental disorder 3. epilepsy and other neurological disorder 4. hypertension and other

Design outcomes

Primary

MeasureTime frame
Patients receiving intramuscular ketamine as adjuvant treatment will show better response than the patients receiving placeboTimepoint: 1.5 Years—

Secondary

MeasureTime frame
If there is any improvement in suicidal ideationTimepoint: 1.5yrs—

Countries

India

Contacts

Public ContactDeborshi Das

Institute of Postgraduate Medical Education and Research

sujitsarkhel@gmail.com9836074700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026